Athera Forms New Scientific Advisory Board – Professors Libby, Simoons, Wallentin and de Faire join
Solna, Sweden, November 11th, 2011 – Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the new Scientific Advisory Board is formed, including professors Peter Libby, Maarten Simoons, Lars Wallentin, and Ulf de Faire.
"We are very pleased to welcome four well-respected medical experts in CVD research as new members of the Scientific Advisory Board," says Per Sjöberg, Chairman of the Board in Athera Biotechnologies " Their tremendous knowledge in cardiovascular disease, vascular inflammation, biomarkers and new treatment approaches is very valuable to Athera, as our projects now are advancing towards the clinic."
Dr Peter Libby is the chief of cardiovascular medicine at Brigham and Women's Hospital and Mallinckrodt Professor of Medicine, Harvard Medical School, both in Boston, USA. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments. His areas of clinical expertise include general and preventive cardiology.
Dr Maarten Simoons is Professor of Cardiology (emeritus) and was Chief of Cardiology, at the Thoraxcenter, Erasmus University Medical Center in Rotterdam, the Netherlands. His research interests include acute and chronic ischemic heart disease, as well as information technology and pharmacogenetics. He was a member of the Board of the European Society of Cardiology and president of the Society 2000-2002. He is a member or the Royal Netherlands Academy of Arts and Science (KNAW).
Dr Lars Wallentin is Professor of Cardiology (emeritus) at the Department of Medical Sciences, Uppsala University Hospital and founder of Uppsala Clinical Research Center (UCR). Over the last 20 years professor Wallentin has been the chairman and principal investigator of many national and international clinical trials of new treatment concepts in cardiac diseases. His group has pioneered the use of molecular biomarkers and new treatments concepts in acute coronary artery diseases.
Dr Ulf de Faire is Professor of Cardiovascular Epidemiology (emeritus) at the Institute of Environmental Medicine, Karolinska Institute, Solna, Sweden. He is active in research on mechanisms and risk factors, involved in the development of atherosclerosis and cardiovascular diseases, and with particular emphasis on genetic mechanisms and biomarkers. Professor de Faire is a scientific founder of Athera.
About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.
PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.
In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.
Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio. www.athera.se
For further Information:
Athera Biotechnologies AB (publ)
Chief Executive Officer
Tel +46 761938190